ADAG - Adagene Enterprise Value

Adagene (ADAG) is developing antibody technologies through partnerships with global behemoths and AI tools while avoiding asset sales. The confirmed price history on the GURU.Markets platform chart, where the Enterprise Value is 67.95, links this to R&D centers in the US and China utilizing external biomanufacturing. The business relies on oncology patents, which guarantee revenue from licenses and the commercialization of intellectual capital.

Patents for the SAFEbody platform create a powerful defensive moat for Adagene in cancer therapy. Analyzing the enterprise value as of the current date allows an investor to see the total cost of acquiring the business. This metric sums the market capitalization and debt, minus cash and cash equivalents. Such a calculation objectively determines the company's real price regardless of liquidity. Intellectual capital makes this indicator resilient to market volatility.